Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Status:
Completed
Trial end date:
2015-03-05
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of
evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.